The U.S. Food and Drug Administration (FDA) has cleared two new mammography reading and workflow optimization software from Siemens Healthineers.
Both Mammovista B.smart and teamplay Mammo Dashboard improve breast imaging analysis workflow, according to the firm. Mammovista B.smart supports breast imaging interpretation across imaging modalities and increases image loading speed by 75%, Siemens said. It uses artificial intelligence algorithms to produce a confidence score in the probability of cancerous tissue.
Teamplay Mammo Dashboard operates on Siemens' teamplay Digital Health platform and produces a snapshot of institution, modality, and exam key performance indicators such as radiation dose, compression, and device utilization, the company said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
